首页 > 最新文献

Expert Review of Molecular Diagnostics最新文献

英文 中文
An overview of point-of-care testing for infections in critically ill patients. 重症患者感染的护理点检测概述。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2024-02-27 DOI: 10.1080/14737159.2024.2322146
Alena Moerman, Jan J De Waele, Jerina Boelens

Introduction: Molecular diagnostic systems for point-of-care (POC) testing are nowadays routinely used and are part of many labs. Although often intended for bedside use outside of the microbiology lab, there is still room for expansion.

Areas covered: This review discusses the two techniques that are currently the most widespread, real-time polymerase-chain reaction (RT-PCR) and loop-mediated isothermal amplification (LAMP). An overview is provided of the various manufacturers and products as well as the evidence and current use in clinical practice. The article further sheds light on some newer techniques, such as CRISPR-based diagnostics and lab-on-a-chip, which are still in development.

Expert opinion: With many new platforms and techniques still in the pipeline and their potential currently not yet fully exploited, we expect the use of molecular POC testing to increase in the years to come. However, even when used in hospital - in lab, the main advantages of the tests being fast and easy to perform already provide significant benefits in terms of patient outcome.

导言:如今,用于护理点(POC)检测的分子诊断系统已成为许多实验室的常规设备。虽然该系统通常用于微生物实验室以外的床边使用,但仍有扩展的空间:本综述讨论了目前最普遍的两种技术:实时聚合酶链反应(RT-PCR)和环介导等温扩增(LAMP)。文章概述了各种制造商和产品以及证据和目前在临床实践中的使用情况。文章还进一步揭示了一些仍在开发中的新技术,如基于 CRISPR 的诊断技术和芯片实验室:专家观点:由于许多新平台和新技术仍在研发过程中,而且其潜力目前尚未得到充分挖掘,我们预计分子 POC 检测的使用在未来几年会越来越多。不过,即使是在医院实验室中使用,检测快速、简便的主要优势也能为患者带来显著的疗效。
{"title":"An overview of point-of-care testing for infections in critically ill patients.","authors":"Alena Moerman, Jan J De Waele, Jerina Boelens","doi":"10.1080/14737159.2024.2322146","DOIUrl":"10.1080/14737159.2024.2322146","url":null,"abstract":"<p><strong>Introduction: </strong>Molecular diagnostic systems for point-of-care (POC) testing are nowadays routinely used and are part of many labs. Although often intended for bedside use outside of the microbiology lab, there is still room for expansion.</p><p><strong>Areas covered: </strong>This review discusses the two techniques that are currently the most widespread, real-time polymerase-chain reaction (RT-PCR) and loop-mediated isothermal amplification (LAMP). An overview is provided of the various manufacturers and products as well as the evidence and current use in clinical practice. The article further sheds light on some newer techniques, such as CRISPR-based diagnostics and lab-on-a-chip, which are still in development.</p><p><strong>Expert opinion: </strong>With many new platforms and techniques still in the pipeline and their potential currently not yet fully exploited, we expect the use of molecular POC testing to increase in the years to come. However, even when used in hospital - in lab, the main advantages of the tests being fast and easy to perform already provide significant benefits in terms of patient outcome.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care. 真菌诊断的快速通道:真菌分子诊断在护理点的潜力。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.1080/14737159.2023.2287504
Paul Trubin, Marwan M Azar
{"title":"A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care.","authors":"Paul Trubin, Marwan M Azar","doi":"10.1080/14737159.2023.2287504","DOIUrl":"10.1080/14737159.2023.2287504","url":null,"abstract":"","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138290685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunities and challenges of point of care testing paradigms in the post-COVID era. 后 COVID 时代医疗点检测模式的机遇与挑战。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2024-03-19 DOI: 10.1080/14737159.2024.2330774
Barbara Van Der Pol
{"title":"Opportunities and challenges of point of care testing paradigms in the post-COVID era.","authors":"Barbara Van Der Pol","doi":"10.1080/14737159.2024.2330774","DOIUrl":"10.1080/14737159.2024.2330774","url":null,"abstract":"","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fast detection of bacterial gut pathogens on miniaturized devices: an overview. 微型设备上细菌肠道病原体的快速检测:概述。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2024-02-13 DOI: 10.1080/14737159.2024.2316756
Gratiela Gradisteanu Pircalabioru, Mina Raileanu, Mihai Viorel Dionisie, Irina-Oana Lixandru-Petre, Ciprian Iliescu

Introduction: Gut microbes pose challenges like colon inflammation, deadly diarrhea, antimicrobial resistance dissemination, and chronic disease onset. Development of early, rapid and specific diagnosis tools is essential for improving infection control. Point-of-care testing (POCT) systems offer rapid, sensitive, low-cost and sample-to-answer methods for microbe detection from various clinical and environmental samples, bringing the advantages of portability, automation, and simple operation.

Areas covered: Rapid detection of gut microbes can be done using a wide array of techniques including biosensors, immunological assays, electrochemical impedance spectroscopy, mass spectrometry and molecular biology. Inclusion of Internet of Things, machine learning, and smartphone-based point-of-care applications is an important aspect of POCT. In this review, the authors discuss various fast diagnostic platforms for gut pathogens and their main challenges.

Expert opinion: Developing effective assays for microbe detection can be complex. Assay design must consider factors like target selection, real-time and multiplex detection, sample type, reagent stability and storage, primer/probe design, and optimizing reaction conditions for accuracy and sensitivity. Mitigating these challenges requires interdisciplinary collaboration among scientists, clinicians, engineers, and industry partners. Future efforts are essential to enhance sensitivity, specificity, and versatility of POCT systems for gut microbe detection and quantification, advancing infectious disease diagnostics and management.

导言:肠道微生物带来了结肠发炎、致命腹泻、抗菌药耐药性传播和慢性病发病等挑战。开发早期、快速和特异性诊断工具对于改善感染控制至关重要。床旁检测(POCT)系统为从各种临床和环境样本中检测微生物提供了快速、灵敏、低成本和从样本到答案的方法,具有便携、自动化和操作简单等优点:肠道微生物的快速检测可采用多种技术,包括生物传感器、免疫测定、电化学阻抗光谱、质谱分析和分子生物学。纳入物联网、机器学习和基于智能手机的护理点应用是 POCT 的一个重要方面。在这篇综述中,作者讨论了各种肠道病原体快速诊断平台及其主要挑战:开发有效的微生物检测方法可能很复杂。检测设计必须考虑目标选择、实时和多重检测、样本类型、试剂稳定性和储存、引物/探针设计以及优化反应条件以提高准确性和灵敏度等因素。应对这些挑战需要科学家、临床医生、工程师和行业合作伙伴之间的跨学科合作。未来的努力对于提高用于肠道微生物检测和定量的 POCT 系统的灵敏度、特异性和多功能性,推进传染病诊断和管理至关重要。
{"title":"Fast detection of bacterial gut pathogens on miniaturized devices: an overview.","authors":"Gratiela Gradisteanu Pircalabioru, Mina Raileanu, Mihai Viorel Dionisie, Irina-Oana Lixandru-Petre, Ciprian Iliescu","doi":"10.1080/14737159.2024.2316756","DOIUrl":"10.1080/14737159.2024.2316756","url":null,"abstract":"<p><strong>Introduction: </strong>Gut microbes pose challenges like colon inflammation, deadly diarrhea, antimicrobial resistance dissemination, and chronic disease onset. Development of early, rapid and specific diagnosis tools is essential for improving infection control. Point-of-care testing (POCT) systems offer rapid, sensitive, low-cost and sample-to-answer methods for microbe detection from various clinical and environmental samples, bringing the advantages of portability, automation, and simple operation.</p><p><strong>Areas covered: </strong>Rapid detection of gut microbes can be done using a wide array of techniques including biosensors, immunological assays, electrochemical impedance spectroscopy, mass spectrometry and molecular biology. Inclusion of Internet of Things, machine learning, and smartphone-based point-of-care applications is an important aspect of POCT. In this review, the authors discuss various fast diagnostic platforms for gut pathogens and their main challenges.</p><p><strong>Expert opinion: </strong>Developing effective assays for microbe detection can be complex. Assay design must consider factors like target selection, real-time and multiplex detection, sample type, reagent stability and storage, primer/probe design, and optimizing reaction conditions for accuracy and sensitivity. Mitigating these challenges requires interdisciplinary collaboration among scientists, clinicians, engineers, and industry partners. Future efforts are essential to enhance sensitivity, specificity, and versatility of POCT systems for gut microbe detection and quantification, advancing infectious disease diagnostics and management.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what? 我们已经实现了丙型肝炎感染的单次检测、诊断和治疗,现在该怎么办?
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2024-01-04 DOI: 10.1080/14737159.2023.2292645
Jason Grebely, Susan Matthews, Louise M Causer, Jordan J Feld, Philip Cunningham, Gregory J Dore, Tanya L Applegate

Introduction: Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-care testing technologies capable of detecting current HCV infection in one hour are a 'game-changer.' These tests enable diagnosis and treatment in a single visit, overcoming the barrier of multiple visits that frequently leads to loss to follow-up. Combining point-of-care HCV antibody and RNA tests should improve cost-effectiveness, patient/provider acceptability, and testing efficiency. However, implementing HCV point-of-care testing programs at scale requires multiple considerations.

Areas covered: This commentary explores the need for point-of-care HCV tests, diagnostic strategies to improve HCV testing, key considerations for implementing point-of-care HCV testing programs, and remaining challenges for point-of-care testing (including operator training, quality management, connectivity and reporting systems, regulatory approval processes, and the need for more efficient tests).

Expert opinion: It is exciting that single-visit testing, diagnosis, and treatment for HCV infection have been achieved. Innovations afforded through COVID-19 should facilitate the accelerated development of low-cost, rapid, and accurate tests to improve HCV testing. The next challenge will be to address barriers and facilitators for implementing point-of-care testing to deliver them at scale.

导言:由于目前的诊断途径需要多次就诊,导致患者失去随访机会,因此检测和治疗率较低,阻碍了消除丙型肝炎病毒(HCV)的进程。能够在一小时内检测出当前丙型肝炎病毒感染情况的床旁检测技术是一种 "改变游戏规则的技术"。这些检测可在一次就诊中完成诊断和治疗,克服了多次就诊经常导致失去随访的障碍。结合床旁 HCV 抗体和 RNA 检测可提高成本效益、患者/医疗服务提供者的接受度和检测效率。然而,大规模实施 HCV 床旁检测项目需要多方面的考虑:本评论探讨了对HCV床旁检测的需求、改进HCV检测的诊断策略、实施HCV床旁检测项目的主要考虑因素,以及床旁检测仍面临的挑战(包括操作员培训、质量管理、连接和报告系统、监管审批流程,以及对更高效检测的需求):令人振奋的是,HCV 感染的单次检测、诊断和治疗已经实现。COVID-19 所带来的创新应有助于加快开发低成本、快速、准确的检测方法,从而改善 HCV 检测。下一个挑战将是解决实施护理点检测的障碍和促进因素,以大规模提供这些检测。
{"title":"We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?","authors":"Jason Grebely, Susan Matthews, Louise M Causer, Jordan J Feld, Philip Cunningham, Gregory J Dore, Tanya L Applegate","doi":"10.1080/14737159.2023.2292645","DOIUrl":"10.1080/14737159.2023.2292645","url":null,"abstract":"<p><strong>Introduction: </strong>Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-care testing technologies capable of detecting current HCV infection in one hour are a 'game-changer.' These tests enable diagnosis and treatment in a single visit, overcoming the barrier of multiple visits that frequently leads to loss to follow-up. Combining point-of-care HCV antibody and RNA tests should improve cost-effectiveness, patient/provider acceptability, and testing efficiency. However, implementing HCV point-of-care testing programs at scale requires multiple considerations.</p><p><strong>Areas covered: </strong>This commentary explores the need for point-of-care HCV tests, diagnostic strategies to improve HCV testing, key considerations for implementing point-of-care HCV testing programs, and remaining challenges for point-of-care testing (including operator training, quality management, connectivity and reporting systems, regulatory approval processes, and the need for more efficient tests).</p><p><strong>Expert opinion: </strong>It is exciting that single-visit testing, diagnosis, and treatment for HCV infection have been achieved. Innovations afforded through COVID-19 should facilitate the accelerated development of low-cost, rapid, and accurate tests to improve HCV testing. The next challenge will be to address barriers and facilitators for implementing point-of-care testing to deliver them at scale.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lessons from the pandemic: new best practices in selecting molecular diagnostics for point-of-care testing of infectious diseases in sub-Saharan Africa. 疫情的教训:撒哈拉以南非洲传染病护理点检测选择分子诊断的新最佳实践。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-09 DOI: 10.1080/14737159.2023.2277368
Mamadu Baldeh, Flavia K Bawa, Faiza U Bawah, Martin Chamai, Francis Dzabeng, Waleed M A Jebreel, Jean-Bertin B Kabuya, Shola K Molemodile Dele-Olowu, Erick Odoyo, Dimbintsoa Rakotomalala Robinson, Aubrey J Cunnington

Introduction: Point-of-care molecular diagnostics offer solutions to the limited diagnostic availability and accessibility in resource-limited settings. During the COVID-19 pandemic, molecular diagnostics became essential tools for accurate detection and monitoring of SARS-CoV-2. The unprecedented demand for molecular diagnostics presented challenges and catalyzed innovations which may provide lessons for the future selection of point-of-care molecular diagnostics.

Areas covered: We searched PubMed from January 2020 to August 2023 to identify lessons learned from the COVID-19 pandemic which may impact the selection of point-of-care molecular diagnostics for future use in sub-Saharan Africa. We evaluated this in the context of REASSURED criteria (Real-time connectivity; Ease of specimen collection; Affordable; Sensitive; Specific; User-friendly; Rapid and robust; Equipment free; and Deliverable to users at the point of need) for point-of-care diagnostics for resource-limited settings.

Expert opinion: The diagnostic challenges and successes during the COVID-19 pandemic affirmed the importance of the REASSURED criteria but demonstrated that these are not sufficient to ensure new diagnostics will be appropriate for public health emergencies. Capacity for rapid scale-up of diagnostic testing and transferability of assays, data, and technology are also important, resulting in updated REST-ASSURED criteria. Few diagnostics will meet all criteria, and trade-offs between criteria will need to be context-specific.

简介:护理点分子诊断为资源有限的环境中有限的诊断可用性和可访问性提供了解决方案。在新冠肺炎大流行期间,分子诊断成为准确检测和监测SARS-CoV-2的重要工具。对分子诊断的空前需求带来了挑战和催化创新,这可能为未来选择护理点分子诊断提供经验教训。涵盖的领域:我们从2020年1月至2023年8月搜索了PubMed,以确定从新冠肺炎大流行中吸取的教训,这可能会影响撒哈拉以南非洲未来使用的定点分子诊断的选择。我们在资源有限的环境下,根据合理的护理点诊断标准(实时连接;易于采集样本;价格合理;敏感;特定;用户友好;快速可靠;无设备;可在需要时交付给用户)对此进行了评估。专家意见:新冠肺炎大流行期间的诊断挑战和成功肯定了合理标准的重要性,但表明这些标准不足以确保新的诊断方法适用于公共卫生紧急情况。快速扩大诊断测试的能力以及分析、数据和技术的可转移性也很重要,从而更新REST-ASSURED标准。很少有诊断能够满足所有标准,标准之间的权衡需要根据具体情况进行。
{"title":"Lessons from the pandemic: new best practices in selecting molecular diagnostics for point-of-care testing of infectious diseases in sub-Saharan Africa.","authors":"Mamadu Baldeh, Flavia K Bawa, Faiza U Bawah, Martin Chamai, Francis Dzabeng, Waleed M A Jebreel, Jean-Bertin B Kabuya, Shola K Molemodile Dele-Olowu, Erick Odoyo, Dimbintsoa Rakotomalala Robinson, Aubrey J Cunnington","doi":"10.1080/14737159.2023.2277368","DOIUrl":"10.1080/14737159.2023.2277368","url":null,"abstract":"<p><strong>Introduction: </strong>Point-of-care molecular diagnostics offer solutions to the limited diagnostic availability and accessibility in resource-limited settings. During the COVID-19 pandemic, molecular diagnostics became essential tools for accurate detection and monitoring of SARS-CoV-2. The unprecedented demand for molecular diagnostics presented challenges and catalyzed innovations which may provide lessons for the future selection of point-of-care molecular diagnostics.</p><p><strong>Areas covered: </strong>We searched PubMed from January 2020 to August 2023 to identify lessons learned from the COVID-19 pandemic which may impact the selection of point-of-care molecular diagnostics for future use in sub-Saharan Africa. We evaluated this in the context of REASSURED criteria (Real-time connectivity; Ease of specimen collection; Affordable; Sensitive; Specific; User-friendly; Rapid and robust; Equipment free; and Deliverable to users at the point of need) for point-of-care diagnostics for resource-limited settings.</p><p><strong>Expert opinion: </strong>The diagnostic challenges and successes during the COVID-19 pandemic affirmed the importance of the REASSURED criteria but demonstrated that these are not sufficient to ensure new diagnostics will be appropriate for public health emergencies. Capacity for rapid scale-up of diagnostic testing and transferability of assays, data, and technology are also important, resulting in updated REST-ASSURED criteria. Few diagnostics will meet all criteria, and trade-offs between criteria will need to be context-specific.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71422008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential for rapid antigen testing for mucormycosis in the context of COVID-19. 在 COVID-19 的背景下进行粘孢子虫病快速抗原检测的潜力。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-07-07 DOI: 10.1080/14737159.2023.2233906
Christopher R Thornton

Introduction: Mucormycosis is a highly aggressive angio-invasive disease of humans caused by Mucorales fungi. Prior to the COVID-19 pandemic, mucormycosis was a rare mycosis typically seen in immunocompromised patients with hematological malignancies or in transplant recipients. During the second wave of the pandemic, there was a dramatic increase in the disease, especially in India where a unique set of circumstances led to large numbers of life-threatening and disfiguring rhino-orbital-cerebral mucormycosis (ROCM) infections.

Areas covered: The review examines mucormycosis as a super-infection of COVID-19 patients, and the risk factors for COVID-19-associated mucormycosis (CAM) that drove the ROCM epidemic in India. The limitations of current diagnostic procedures are identified, and the measures needed to improve the speed and accuracy of detection discussed.

Expert opinion: Despite increased awareness, global healthcare systems remain unprepared for further outbreaks of ROCM. Current diagnosis of the disease is slow and inaccurate, negatively impacting on patient survival. This is most evident in low- to middle-income countries which lack suitably equipped diagnostic facilities for rapid identification of the infecting pathogens. Rapid antigen testing using point-of-care lateral-flow assays could potentially have aided in the quick and accurate diagnosis of the disease, allowing earlier intervention with surgery and Mucorales-active antifungal drugs.

简介粘孢子菌病是由粘孢子菌引起的一种侵袭性很强的血管侵袭性疾病。在 COVID-19 大流行之前,粘孢子菌病是一种罕见的真菌病,通常见于免疫力低下的血液恶性肿瘤患者或移植受者。在第二波大流行期间,这种疾病急剧增加,尤其是在印度,那里的一系列特殊情况导致了大量危及生命和毁容的鼻-眶-脑粘孢子菌病(ROCM)感染:综述探讨了作为 COVID-19 患者超级感染的粘孢子菌病,以及导致印度 ROCM 流行的 COVID-19 相关粘孢子菌病 (CAM) 的风险因素。确定了当前诊断程序的局限性,并讨论了提高检测速度和准确性所需的措施:专家观点:尽管人们对该疾病的认识有所提高,但全球医疗保健系统仍未做好应对 ROCM 进一步爆发的准备。目前对该疾病的诊断既缓慢又不准确,对患者的生存造成了负面影响。这种情况在中低收入国家最为明显,这些国家缺乏设备齐全的诊断设施,无法快速识别感染病原体。使用护理点侧向流检测法进行快速抗原检测可能有助于快速、准确地诊断该疾病,从而可以更早地进行手术和使用黏菌类抗真菌药物。
{"title":"The potential for rapid antigen testing for mucormycosis in the context of COVID-19.","authors":"Christopher R Thornton","doi":"10.1080/14737159.2023.2233906","DOIUrl":"10.1080/14737159.2023.2233906","url":null,"abstract":"<p><strong>Introduction: </strong>Mucormycosis is a highly aggressive angio-invasive disease of humans caused by Mucorales fungi. Prior to the COVID-19 pandemic, mucormycosis was a rare mycosis typically seen in immunocompromised patients with hematological malignancies or in transplant recipients. During the second wave of the pandemic, there was a dramatic increase in the disease, especially in India where a unique set of circumstances led to large numbers of life-threatening and disfiguring rhino-orbital-cerebral mucormycosis (ROCM) infections.</p><p><strong>Areas covered: </strong>The review examines mucormycosis as a super-infection of COVID-19 patients, and the risk factors for COVID-19-associated mucormycosis (CAM) that drove the ROCM epidemic in India. The limitations of current diagnostic procedures are identified, and the measures needed to improve the speed and accuracy of detection discussed.</p><p><strong>Expert opinion: </strong>Despite increased awareness, global healthcare systems remain unprepared for further outbreaks of ROCM. Current diagnosis of the disease is slow and inaccurate, negatively impacting on patient survival. This is most evident in low- to middle-income countries which lack suitably equipped diagnostic facilities for rapid identification of the infecting pathogens. Rapid antigen testing using point-of-care lateral-flow assays could potentially have aided in the quick and accurate diagnosis of the disease, allowing earlier intervention with surgery and Mucorales-active antifungal drugs.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9769747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention. 护理点尿液替诺福韦依从性监测,推动艾滋病治疗和预防干预。
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2024-02-14 DOI: 10.1080/14737159.2024.2312122
Matthew Spinelli, Monica Gandhi

Introduction: Although effective antiretroviral and pre-exposure prophylaxis/PrEP regimens are available globally, adherence challenges persist. Objective measures of adherence can both measure adherence accurately and can be used to drive interventions. The first point-of-care pharmacologic adherence measure, urine tenofovir testing using a lateral flow assay, is now available.

Areas covered: This review examines the ability of pharmacologic metrics of adherence to predict HIV and PrEP clinical outcomes and the past use of pharmacologic metrics of adherence as tools to drive adherence interventions. The success of preliminary studies using point-of-care adherence metrics to guide interventions is then discussed.

Expert opinion: Large randomized clinical trials are now needed to test the impact of point-of-care adherence interventions on HIV and PrEP clinical outcomes, given promising results of the pilot studies summarized here. Hybrid implementation-effectiveness studies will be needed to examine optimal approaches to incorporating point-of-care testing into routine clinical care delivery, including in guiding resistance testing, adherence counseling, and delivery of other evidence-based adherence interventions. Given the ability of point-of-care tenofovir testing to be implemented in settings where viral load testing is not available, and at more frequent intervals due to its low cost, urine-based tenofovir assays have the potential to be highly scalable in diverse clinical settings.

导言:尽管全球范围内都有有效的抗逆转录病毒疗法和暴露前预防疗法/PrEP 方案,但在坚持治疗方面仍然存在挑战。客观的依从性测量方法既能准确测量依从性,又能用于推动干预措施。首个护理点药理依从性测量方法--使用侧流检测法进行尿液替诺福韦检测--现已问世:本综述探讨了药理学依从性指标预测艾滋病和 PrEP 临床结果的能力,以及过去将药理学依从性指标用作推动依从性干预的工具的情况。然后讨论了使用护理点依从性指标指导干预措施的初步研究的成功之处:专家意见:鉴于本文总结的试点研究取得了令人鼓舞的成果,现在需要进行大型随机临床试验,以检验护理点依从性干预措施对 HIV 和 PrEP 临床结果的影响。还需要开展混合实施效果研究,以检验将护理点检测纳入常规临床护理服务的最佳方法,包括指导耐药性检测、依从性咨询以及提供其他循证依从性干预措施。鉴于尿基替诺福韦检测能够在无法进行病毒载量检测的环境中进行,而且由于其成本低廉,检测频率更高,因此尿基替诺福韦检测有可能在不同的临床环境中高度推广。
{"title":"Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention.","authors":"Matthew Spinelli, Monica Gandhi","doi":"10.1080/14737159.2024.2312122","DOIUrl":"10.1080/14737159.2024.2312122","url":null,"abstract":"<p><strong>Introduction: </strong>Although effective antiretroviral and pre-exposure prophylaxis/PrEP regimens are available globally, adherence challenges persist. Objective measures of adherence can both measure adherence accurately and can be used to drive interventions. The first point-of-care pharmacologic adherence measure, urine tenofovir testing using a lateral flow assay, is now available.</p><p><strong>Areas covered: </strong>This review examines the ability of pharmacologic metrics of adherence to predict HIV and PrEP clinical outcomes and the past use of pharmacologic metrics of adherence as tools to drive adherence interventions. The success of preliminary studies using point-of-care adherence metrics to guide interventions is then discussed.</p><p><strong>Expert opinion: </strong>Large randomized clinical trials are now needed to test the impact of point-of-care adherence interventions on HIV and PrEP clinical outcomes, given promising results of the pilot studies summarized here. Hybrid implementation-effectiveness studies will be needed to examine optimal approaches to incorporating point-of-care testing into routine clinical care delivery, including in guiding resistance testing, adherence counseling, and delivery of other evidence-based adherence interventions. Given the ability of point-of-care tenofovir testing to be implemented in settings where viral load testing is not available, and at more frequent intervals due to its low cost, urine-based tenofovir assays have the potential to be highly scalable in diverse clinical settings.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care tests: the key to reducing antibiotic prescribing for respiratory tract infections in primary care? 护理点检测:减少基层医疗机构呼吸道感染抗生素处方的关键?
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-05-24 DOI: 10.1080/14737159.2023.2217330
Emily Brown, Alastair D Hay
{"title":"Point-of-care tests: the key to reducing antibiotic prescribing for respiratory tract infections in primary care?","authors":"Emily Brown, Alastair D Hay","doi":"10.1080/14737159.2023.2217330","DOIUrl":"10.1080/14737159.2023.2217330","url":null,"abstract":"","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9569506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma. 开发与再生相关的microRNA作为改善肝功能衰竭综合征和肝细胞癌预后的生物标志物的挑战和潜力
IF 5.1 3区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-12-19 DOI: 10.1080/14737159.2023.2292642
Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare

Introduction: Determining the need for liver transplantation remains critical in the management of hepatocellular carcinoma (HCC) and liver failure syndromes (including acute liver failure and decompensated cirrhosis states). Conventional prognostic models utilize biomarkers of liver and non-liver failure and have limitations in their application. Novel biomarkers which predict regeneration may fulfil this niche. microRNA are implicated in health and disease and are present in abundance in the circulation. Despite this, they have not translated into mainstream clinical biomarkers.

Areas covered: We will discuss current challenges in the prognostication of patients with liver failure syndromes as well as for patients with HCC. We will discuss biomarkers implicated with liver regeneration. We then provide an overview of the challenges in developing microRNA into clinically tractable biomarkers. Finally, we will provide a scoping review of microRNA which may have potential as prognostic biomarkers in liver failure syndromes and HCC.

Expert opinion: Novel biomarkers are needed to improve prognostic models in liver failure syndromes and HCC. Biomarkers associated with liver regeneration are currently lacking and may fulfil this niche. microRNA have the potential to be developed into clinically tractable biomarkers but a consensus on standardizing methodology and reporting is required prior to large-scale studies.

在肝细胞癌(HCC)和肝功能衰竭综合征(包括急性肝功能衰竭和失代偿肝硬化状态)的治疗中,确定是否需要肝移植仍然至关重要。传统的预后模型利用肝和非肝衰竭的生物标志物,在应用上有局限性。预测再生的新型生物标记物可能会填补这一空缺。microRNA与健康和疾病有关,在血液循环中大量存在。尽管如此,它们还没有转化为主流的临床生物标志物。涵盖领域:我们将讨论当前肝衰竭综合征患者和HCC患者预后方面的挑战。我们将讨论与肝脏再生有关的生物标志物。然后,我们概述了将microRNA开发成临床可处理的生物标志物所面临的挑战。最后,我们将对可能作为肝衰竭综合征和HCC预后生物标志物的microRNA进行综述。专家意见:需要新的生物标志物来改善肝衰竭综合征和HCC的预后模型。目前缺乏与肝脏再生相关的生物标志物,可能会填补这一空缺。microRNA有潜力发展成为临床可处理的生物标志物,但在大规模研究之前,需要在标准化方法和报告方面达成共识。
{"title":"The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma.","authors":"Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare","doi":"10.1080/14737159.2023.2292642","DOIUrl":"10.1080/14737159.2023.2292642","url":null,"abstract":"<p><strong>Introduction: </strong>Determining the need for liver transplantation remains critical in the management of hepatocellular carcinoma (HCC) and liver failure syndromes (including acute liver failure and decompensated cirrhosis states). Conventional prognostic models utilize biomarkers of liver and non-liver failure and have limitations in their application. Novel biomarkers which predict regeneration may fulfil this niche. microRNA are implicated in health and disease and are present in abundance in the circulation. Despite this, they have not translated into mainstream clinical biomarkers.</p><p><strong>Areas covered: </strong>We will discuss current challenges in the prognostication of patients with liver failure syndromes as well as for patients with HCC. We will discuss biomarkers implicated with liver regeneration. We then provide an overview of the challenges in developing microRNA into clinically tractable biomarkers. Finally, we will provide a scoping review of microRNA which may have potential as prognostic biomarkers in liver failure syndromes and HCC.</p><p><strong>Expert opinion: </strong>Novel biomarkers are needed to improve prognostic models in liver failure syndromes and HCC. Biomarkers associated with liver regeneration are currently lacking and may fulfil this niche. microRNA have the potential to be developed into clinically tractable biomarkers but a consensus on standardizing methodology and reporting is required prior to large-scale studies.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Molecular Diagnostics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1